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CAMPTOTHECIN INTERMEDIATES AND
PRODRUGS AND METHODS OF
PREPARATION THEREOF

These agents display a unique mechanism of action: stabi
liZation of the covalent binding of the enZyme topoi
somerase I (topo I), an intranuclear enZyme that is overex

This application claims the bene?t of Us. Provisional
Patent Application Ser. No. 60/469,754 ?led on May 12,

pressed in a variety of tumor lines, to DNA. This drug/
5

2003.
This invention Was made With Government support under
NIH Grant Number lR0lCA63653. The Government may 10

have certain rights in this invention.

TECHNICAL FIELD

enzyme/DNA complex leads to reversible, single strand
nicks Which, according to the fork collision model, promote
irreversible and lethal double strand DNA breaks during

replication.
The camptothecin class of anticancer agents have exhib
ited unusual reactivity in vivo, both With respect to drug
hydrolysis and blood protein interactions. These factors
have hindered the pharmaceutical development and clinical
implementation of camptothecins. In terms of hydrolysis,
each of the camptothecins shoWn in FIG. 1 contains an

ot-hydroxy-d-lactone pharmacophore. At physiological pH

The present invention relates to novel intermediates and

of 7 and above this functionality is reactive, readily con

prodrugs of camptothecins.

verting to the biologically inactive “ring opened” carboxy
20

BACKGROUND OF THE INVENTION

late form. Thus, as a result of the labile ot-hydroxy-d-lactone
pharmacophore, an equilibrium is established betWeen tWo

distinct drug species: 1) the biologically active lactone form
Where the lactone ring remains closed; and 2) a biologically
The anticancer agent camptothecin and related com
pounds (FIG. 1) are emerging as an important class of agents 25 inactive carboxylate form generated upon the hydrolysis of
the lactone ring of the parent drug. In this invention We
useful in the treatment of cancer.
describe novel intermediates and prodrugs of camptothecin
FIG. 1. Clinical candidates and FDA-approved analogs in

and related analogs.

the camptothecin family of antitumor agents

Aqueous
Solubility

Compound

R10

R1

R2

Soluble

Topotecan/TPT

H

CH2NH(CH3)2

OH

H

"

CDK602

H

C2H5NHCH(CH3)2

H

H

Irinotecan/CPT-ll

CZH5

H

O

<

GI-l472llC/GG-2ll

N

N J'L O —

H
— CH2— N

R3

O

\

N — CH3

0/
Insoluble

Calnptothecin

H

H

H

"

9-AC

H

NH2

H

H
H

9-NC/Rubitecan
SN-3 8
DB-67

H
C2H5
Si(CH3)2C(CH3)3

N02
H
H

H
OH
OH

H
H
H

MDCPT

H

H

O—

US 7,064,202 B1
4

3
DETAILED DESCRIPTION OF THE
INVENTION

a (CH2)YNR8R9 group, WhereinY is an integer from lil0

and R8 and R9 are, independently, hydrogen, an alkyl
group, an alkenyl group, an alkynyl group, an amine, an

The invention includes camptothecin lactam intermedi
ates With the following structure A:

5

alkyl amine, a dialkyl amine, a hydroxy group, an alkoxy
group, an acyl group, a carbamate; c) R8, R9 and the
nitrogen to Which they are attached may be taken together
to form a saturated or unsaturated three to ten membered

heterocyclic ring; d) R3 may be linked to R4 as R (CH2)
GR4 Wherein G may be an integer from 1e10, additionally
this ring may contain one or more NH, O or S atoms in
place of one or more 4CH2i groups;

R4 may be hydrogen, a halogen atom, a hydroxy group, an
amino group, a methoxy group, an alkyl group, an alkynyl
group or an alkenyl group;

R5 may be hydrogen or ?uorine;
R6 may be an alkyl group, an alkenyl group, an alkynyl
group, or a benZyl group;

R7 may be hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, a benZyl group, an alkoxy group, an
aryloxy group, or an acyloxy group; and pharmaceutically

acceptable salts thereof.
The invention includes camptothecin ortho lactone inter
mediates and prodrugs With the folloWing structure B:

where R1 may be: a) hydrogen, a halogen atom, a branched
or linear alkyl group, a branched or linear alkenyl group,
a branched or linear alkynyl group, a cycloalkyl group, a

25

cycloalkenyl group, an alkoxy group, an alkylamino
group, a dialkylamino group, an alkylthiol group, a thiol
group, a phenyl group, an amino group, a nitro group, a

cyano group; b) a (CH2)YNR8R9 group, Wherein Y is an

integer from lil0 and R8 and R9 are, independently,

30

hydrogen, an alkyl group, an alkenyl group, an alkynyl
group, an amine, an alkyl amine, a dialkyl amine, a
hydroxy group, an alkoxy group, an acyl group, a car

bamate; c) R8, R9 and the nitrogen to Which they are
attached may be taken together to form a saturated or

35

unsaturated three to ten membered heterocyclic ring
Which may contain 0, S, NR1O where R10 is hydrogen, an
alkyl group, an alkenyl group, an alkynyl group, an
alkoxy group or a carbamate; d) R1 may be linked to R2

as Rl(CH2)QR2 Wherein Q represents an integer 1e10, 40 where R1 may be: a) hydrogen, a halogen atom, a branched
additionally this ring may contain one or more NH, O or
S atoms in place of one or more 4CH2i groups;

or linear alkyl group, a branched or linear alkenyl group,
a branched or linear alkynyl group, a cycloalkyl group, a

R2 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl group,

cycloalkenyl group, an alkoxy group, an alkylamino

a linear or branched alkynyl group, an amino group, an

group, a phenyl group, an amino group, a nitro group, a

alkylamino group, a dialkylamino group, a nitro group, a

cyano group; b) a (CH2)YNR8R9 group, Wherein Y is an

group, a dialkylamino group, an alkylthiol group, a thiol

integer from lil0 and R8 and R9 are, independently,

3*l0 membered heterocyclic ring, a C3_ 10 cycloalkyl
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl
group, a thiol group, a cyano group; b) a (CH2)YNR8, R9
group, Wherein Y is an integer from lil0 and R8 and R9

hydrogen, an alkyl group, an alkenyl group, an alkynyl
group, an amine, an alkyl amine, a dialkyl amine, a
50

hydroxy group, an alkoxy group, an acyl group, a car

bamate; c) R8, R9 and the nitrogen to Which they are

are, independently, hydrogen, an alkyl group, an alkenyl
group, an alkynyl group, an amine, an alkyl amine, a

attached may be taken together to form a saturated or

dialkyl amine, a hydroxy group, an alkoxy group, an acyl
group, a carbamate; c.) R8, R9 and the nitrogen to Which

unsaturated three to ten membered heterocyclic ring
Which may contain 0, S, NR1O where R10 is hydrogen, an

they are attached may be taken together to form a satu
rated or unsaturated three to ten membered heterocyclic

ring; d) R2 may be linked to R3 as R2(CH2)GR3 Wherein
G may be an integer from 1e10, additionally this ring may

55

alkyl group, an alkenyl group, an alkynyl group, an
alkoxy group or a carbamate; d) R1 may be linked to R2

as Rl(CH2)QR2 Wherein Q represents an integer 1e10,

additionally, this ring may contain one or more NH, O or
S atoms in place of one or more iCHZi groups;
more 4CH2i groups;
60 R2 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl group,
R3 may be: a) hydrogen, a halogen atom, a linear or
a linear or branched alkynyl group, an amino group, an
branched alkyl group, a linear or branched alkenyl group,
a linear or branched alkynyl group, an amino group, an
alkylamino group, a dialkylamino group, a nitro group, a
3*l0 membered heterocyclic ring, a C3_1O cycloalkyl
alkylamino group, a dialkylamino group, a nitro group, a
contain one or more NH, O or S atoms in place of one or

3*l0 membered heterocyclic ring, a C3_ 10 cycloalkyl
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl

group, a C3_1O cycloalkenyl group, a C8_1O cycloalkynyl

group, a thiol group, a cyano group, a hydroxyl group; b)

group, Wherein Y is an integer from lil0 and R8 and R9

group, a thiol group, a cyano group; b) a (CH2)YNR8R9

US 7,064,202 B1
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are, independently, hydrogen, an alkyl group, an alkenyl

attached may be taken together to form a saturated or

group, an alkynyl group, an amine, an alkyl amine, a

unsaturated three to ten membered heterocyclic ring
Which may contain 0, S, NR1O where R10 is hydrogen, an

dialkyl amine, a hydroxy group, an alkoxy group, an acyl
group, a carbamate; c) R8, R9 and the nitrogen to Which

alkyl group, an alkenyl group, an alkynyl group, an
alkoxy group or a carbamate; d) R1 may be linked to R2

they are attached may be taken together to form a satu
rated or unsaturated three to ten membered heterocyclic

as Rl(CH2)QR2 Wherein Q represents an integer 1e10,

ring; d) R2 may be linked to R3 as R2(CH2)GR3 Wherein
G may be an integer from 1e10, additionally this ring may

additionally this ring may contain one or more NH, O or
S atoms in place of one or more iCHZi groups;

contain one or more NH, O or S atoms in place of one or

R2 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl group,

more 4CH2i groups;

R3 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl group,

a linear or branched alkynyl group, an amino group, an

alkylamino group, a dialkylamino group, a nitro group, a

a linear or branched alkynyl group, an amino group, an

3*l0 membered heterocyclic ring, a C3_1O cycloalkyl

alkylamino group, a dialkylamino group, a nitro group, a

group, a C3_1O cycloalkenyl group, a C8_1O cycloalkynyl

3*l0 membered heterocyclic ring, a C3_ 10 cycloalkyl
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl

group, a thiol group, a cyano group; b) a (CH2)YNR8R9

group, Wherein Y is an integer from lil0 and R8 and R9
are, independently, hydrogen, an alkyl group, an alkenyl

group, a thiol group, a cyano group, a hydroxyl group; b)

a (CH2)YNR8R9 group, WhereinY is an integer from lil0

group, an alkynyl group, an amine, an alkyl amine, a

and R8 and R9 are, independently, hydrogen, an alkyl

dialkyl amine, a hydroxy group, an alkoxy group, an acyl
group, a carbamate; c) R8, R9 and the nitrogen to Which

group, an alkenyl group, an alkynyl group, an amine, an

20

they are attached may be taken together to form a satu
rated or unsaturated three to ten membered heterocyclic

alkyl amine, a dialkyl amine, a hydroxy group, an alkoxy
group, an acyl group, a carbamate c) R8, R9 and the
nitrogen to Which they are attached may be taken together

ring; d) R2 may be linked to R3 as R2(CH2)GR3 Wherein
G may be an integer from 1e10, additionally this ring may

to form a saturated or unsaturated three to ten membered

heterocyclic ring; d) R3 may be linked to R4 as R3
(CH2)GR4 Wherein G may be an integer from 1e10,

25

R3 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl group,

additionally this ring may contain one or more NH, O or
S atoms in place of one or more 4CH2i groups;

R4 may be hydrogen, a halogen atom, a hydroxy group, an
amino group, a methoxy group, an alkyl group, an alkynyl

contain one or more NH, O or S atoms in place of one or

more 4CH2i groups;

a linear or branched alkynyl group, an amino group, an
30

alkylamino group, a dialkylamino group, a nitro group, a

R5 may be hydrogen or ?uorine;

3*l0 membered heterocyclic ring, a C3_1O cycloalkyl
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl

R6 may be an alkyl group, an alkenyl group, an alkynyl

group, a thiol group, a cyano group, a hydroxyl group; b)

group or an alkenyl group;

a (CH2)YNR8R9 group, WhereinY is an integer from lil0

group, or a benZyl group; and

R7 may be hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, a benZyl group, an alkoxy group, an
aryloxy group, or an acyloxy group; and pharmaceutically

acceptable salts thereof.
The invention also includes camptothecin intermediates
and prodrugs With the folloWing structure C:

35

and R8 and R9 are, independently, hydrogen, an alkyl
group, an alkenyl group, an alkynyl group, an amine, an

alkyl amine, a dialkyl amine, a hydroxy group, an alkoxy
group, an acyl group, a carbamate c) R8, R9 and the
nitrogen to Which they are attached may be taken together
40

to form a saturated or unsaturated three to ten membered

heterocyclic ring; d) R3 may be linked to R4 as R3
(CH2)GR4 Wherein G may be an integer from 1e10,
additionally this ring may contain one or more NH, O or
S atoms in place of one or more iCHZi groups;

R1
45

R4 may be hydrogen, a halogen atom, a hydroxy group, an
amino group, a methoxy group, an alkyl group, an alkynyl
group or an alkenyl group;

OR8

R5 may be hydrogen or ?uorine;
50

R6 may be an alkyl group, an alkenyl group, an alkynyl
group, a benZyl group, an alkoxy group, an aryloxy group,
or an acyloxy group;

on

R7 may be hydrogen, an alkyl group, an alkenyl group, a

NR7| w
0

benZyl group, an alkoxy group, an aryloxy group, or an

acyloxy group; and
55

R8 may be hydrogen, an alkyl group, or an alkenyl group;

and pharmaceutically acceptable salts thereof.
All compounds of the present invention including the

where R1 may be: a) hydrogen, a halogen atom, a branched
or linear alkyl group, a branched or linear alkenyl group,
a branched or linear alkynyl group, a cycloalkyl group, a

[3-hydroxylactone group can exist in racemic form, enantio

cycloalkenyl group, an alkoxy group, an alkylamino

merically enriched from, and enantiomerically pure form.

group, a dialkylamino group, an alkylthiol group, a thiol

60

The formulas of such compounds as set forth herein cover

and/or include each such form.

group, a phenyl group, an amino group, a nitro group, a

cyano group; b) a (CH2)YNR8R9 group, Wherein Y is an

The terms “alkyl”, “aryl” and other groups refer generally

integer from lil0 and R8 and R9 are, independently,

to both unsubstituted and substituted groups unless speci?ed
to the contrary. Unless otherWise speci?ed, alkyl groups are
hydrocarbon groups and are preferably C liC 1 5 (that is,
having 1 to 15 carbon atoms) alkyl groups, and more
preferably CFC1O alkyl groups, and can be branched or

hydrogen, an alkyl group, an alkenyl group, an alkynyl
group, an amine, an alkyl amine, a dialkyl amine, a
hydroxy group, an alkoxy group, an acyl group, a car

bamate; or c) R8, R9 and the nitrogen to Which they are

65
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unbranched, acyclic or cyclic. The above de?nition of an
alkyl group and other de?nitions apply also When the group
is a substituent on another group (for example, an alkyl

preparation of the compounds of the present invention and

group as a substituent of an alkylamino group or a dialky

E-ring (the lactone ring) may be opened With alkali metal

their pharmaceutically acceptable salts.
For puri?cation, administration or other purposes, the

lamino group). The term “aryl” refers to phenyl or napthyl.

such as, but not limited to, sodium hydroxide or calcium

As used herein, the terms “halogen” or “halo” refer to ?uoro,

hydroxide, to form opened E-ring analogs of compounds of

chloro, bromo and iodo.
The term “alkoxy” refers to 4ORd, Wherein Rd is an alkyl

structures A, B and C. The intermediates thus obtained are
more soluble in Water and may be puri?ed to produce, after
treatment With an acid, a puri?ed form of the camptothecin

group. The term “aryloxy” refers to ‘0R8, Wherein Re is an

analogs of the present invention.
All the novel compounds of the present invention Whether
in racemic, enantiomerically enriched or enantiomerically
pure form display good biological activity While also pos
sessing favorable characteristics for active loading into

aryl group. The term acyl refers to iC(O)Rf. The term
“alkenyl” refers to a straight or branched chain hydrocarbon
group With at least one double bond, preferably With 2*15
carbon atoms, and more preferably With 2*10 carbon atoms

(for example, iCH=CHRg or 4CH2CH=CHRg). The

liposomal particle drug delivery systems of the micelle type

term “alkynyl” refers to a straight or branched chain hydro
carbon group With at least one triple bond, preferably With
2*15 carbon atoms, and more preferably With 2*10 carbon

disclosed and described in Us. Pat. Nos. 5,316,771; 5,552,
156 and 5,736,156. Pre-made liposomes can be ef?ciently
loaded With any of the novel compounds of structures A, B

atoms (for example, iCECRh or iCHzCsCRh). The terms
“alkylene,” “alkenylene” and “alkynylene” refer to bivalent

forms of alkyl, alkenyl and alkynyl groups, respectively.

and C of this invention using pH gradients.
20

variety of substituents to synthesiZe homocamptothecin ana

logs retaining activity. For example, alkyl groups may
preferably be substituted With a group or groups including,
but not limited to, a benZyl group, a phenyl group, an alkoxy
group, a hydroxy group, an amino group (including, for

25

example, free amino groups, alkylamino, dialkylamino

some particle can result in diffusion or active loading of the
compound/agent of the present invention inWard to the core
of the particle. The chemical gradient across the membrane
creates a driving force for the compound/ agent to replace the

lost NH3 from the interior of the liposome. Once inside the
acidic con?nes of the core, the compound/agent becomes
protonated and remains Within the core, as its positive

groups and arylamino groups), an alkenyl group, an alkynyl
group and an acyloxy group. In the case of amino groups

(iNRaRb), R“ and Rh are preferably independently hydro

In brief, in the active core loading process an amine

containing agent is loaded into the particle. For example, a
gradient created by ammonia gas diffusing out of the lipo

The groups set forth above, can be substituted With a Wide

30

charge impedes retro-di?‘usion across the liposome bilayer.
The protonated amine also prevents the occurrence of
nucleophilic attack of the amine on the lactone carbonyl. As

gen, an acyl group, an alkyl group, or an aryl group. Acyl

groups may preferably be substituted With (that is, Rf is) an
alkyl group, a haloalkyl group (for example, a per?uoroalkyl
be substituted With (that is, Rg and Rh are preferably) a group

liposomes can be actively and/or passively targeted to the
tumor, the liposome encapsulated compound/agent can be
effectively concentrated at the tumor site, therby reducing
exposure of the healthy host tissues to the cytotoxic agent

or groups including, but not limited to, an alkyl group, an

yet enhancing exposure at the tumor target.

group), an alkoxy group, an amino group and a hydroxy

group. Alkynyl groups and alkenyl groups may preferably

35

The tumor targeted approach involving liposomal deliv

alkoxyalkyl group, an amino alkyl group and a benZyl
group.
The term “acyloxy” as used herein refers to the group

40

ery of core loaded compound/agent addresses multiple clini
cal issues. For example, reduced systemic toxicity can be

45

achieved. Enhanced exposure at the tumor site in terms of
relative amounts of drug reaching the tumor can also be
achieved. Furthermore, enhanced exposure at the tumor site
can be achieved in terms of prolonging the exposure of drug
there.

iOC(O)Rd.
The term “alkoxycarbonyloxy” as used herein refers to

the group 4OC(O)ORd.
The term “carbamoyloxy” as used herein refers to the

group 4OC(O)NR“Rb.
Amino and hydroxy groups may include protective
groups as knoWn in the art. Preferred protective groups for

The present invention also provides a method of treating
a patient, Which comprises administering a pharmaceutically

amino groups include ter‘t-butyloxycarbonyl, formyl, acetyl,
benZyl, p-methoxybenZyloxycarbonyl, trityl. Other suitable

effective amount of a compound of structures A, B and/or C
or a pharmaceutically acceptable salt thereof. The com

protecting groups as knoWn to those skilled in the art are

disclosed in Greene, T., Wuts, P. G. M., Protective Groups
in Organic Synthesis, Wiley (1991), the disclosure of Which
is incorporated herein by reference.
In general, R1, R2 and R3 are preferably not excessively
bulky to maintain activity of the resultant camptothecin

50

pound may, for example, be administered to a patient
al?icted With cancer and/or leukemia. The compounds of the
present invention may also act as antiviral (for example,

anti-HIV) agents and antiparasitic agents. The pharmaceu
tically effective amount or dosage is preferably betWeen 0.01
55

to 80 mg of one of the compounds of structures A, B and/or

analog. Preferably, therefore, R1, R2 and R3 independently

C per kg of body Weight. More preferably, the pharmaceu

have a molecular Weight less than approximately 250. More

tically effective amount or dosage is preferably betWeen 0.1

preferably R1, R2 and R3 independently have a molecular
Weight less than approximately 200.
Some of the camptothecin analogs of the present inven

to 40 mg of one of the compounds of structures A, B and/or

C per kg of body Weight. In general, a pharmaceutically
60

inorganic acids such as, but not limited to, hydrochloride,

hydrobromide, sulfate, phosphate, and nitrate. The camp
tothecin analogs can also be prepared as salts With organic
acids such as, but not limited to, acetate, tartrate, fumarate,

effective amount or dosage contains an amount of one of the

compounds of structures A, B and/or C effective to display
antileukemic and/or antitumor (anticancer) behavior. Phar
maceutical compositions containing as an active ingredient

tion can be prepared for pharmaceutical use as salts With

of one of the compounds of structures A, B and/or C or a
65

pharmaceutically acceptable salt thereof in association With

succinate, citrate, methanesulfonate, p-toluenesulfonate, and

a pharmaceutically acceptable carrier or diluent are also

stearate. Other acids can be used as intermediates in the

Within the scope of the present invention.

US 7,064,202 B1
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The folloWing examples are presented to further illustrate

The compounds of the present invention may be admin
istered as a pharmaceutical composition containing the
compounds and a pharmaceutically acceptable carrier or

the invention, but it is not to be considered as limited thereto.

diluent. The compounds can also be administered as their

ring open salt forms, since relactoniZation to their active

5

EXAMPLE 1

forms can occur in the body (especially at sites of reduced
pH). The active material can also be mixed With other active
materials Which do not impair the desired action and/or

Preparation of camptothecin and SN-38 20(S)

supplement the desired action. The compounds/active mate

Camptothecin-20(S) (uu-aminoalkanoanic esters Were
synthesiZed by a procedure described by Wall and Wani et
al., With novel modi?cations.

(uu-aminoalkanoanic esters

rials according to the present invention can be administered

by any route, for example, orally, nasally, parenterally,
intravenously, intradermally, subcutaneously, or topically, in
liquid or solid form.

For the purposes of parenteral therapeutic administration,
the active ingredient may be incorporated into a solution or
suspension. The solutions or suspensions may also include
the folloWing components: a sterile diluent such as Water:

for injection, suspensions of liposomal particles Whereby the

HO

20

n

n I 1, 2, 3

particles contain stable, active drug Within the core of the
particle in a pH controlled and protected environment or
associated to the outside of the particle or any of the bilayers

of the particle, saline solution, ?xed oils, polyethylene
glycols, glycerine, propylene glycol or other synthetic sol

)ka/ NHBOC

EDCl, DMAP, cnzcl2

25

vents; antibacterial agents such as benZyl alcohol or methyl
parabens; antioxidants such as ascorbic acid or sodium

bisul?te; chelating agents such as ethylenediaminetetraace
tic acid; bulfers such as acetates, citrates or phosphates and

30

agents for the adjustment of tonicity such as sodium chloride
or dextrose. The parenteral preparation can be enclosed in

ampoules, disposable syringes or multiple dose vials made
of glass or plastic.

35

Another mode of administration of the compounds of this
invention is oral. Oral compositions Will generally include
an inert diluent or an edible carrier. They may be enclosed

in gelatin capsules or compressed into tablet. For the pur
pose of oral therapeutic administration, the aforesaid com
pounds may be incorporated With excipients and used in the

40

form of tablets, troches, capsules, elixirs, suspensions, syr
ups, Wafers, cheWing gums and the like.
The tablets, pills, capsules and the like may contain the
folloWing ingredients: a binder such as microcrystalline

45

cellulose, gum tragacanth or gelatin; an excipient such as
starch or lactose, a disintegrating agent such as alginic acid,
Primogel, corn starch and the like; a lubricant such as
magnesium stearate or Sterotes; a glidant such a colloidal
silicon dioxide; and a sWeetening agent such as sucrose or

O

SN-38 uu-aminoalkanoanic esters, because of the presence
of a l0-hydroxy group in addition to the 20(S)4OH, Were
50

synthesiZed by a novel procedure.

saccharin or ?avoring agent such as peppermint, methyl
salicylate, or orange ?avoring may be added. When the
dosage unit is in the form of a capsule, it may contain, in
addition to material of the above type, a liquid carrier such
as a fatty oil. Other dosage unit forms may contain other

various materials Which modify the physical form of the
dosage unit, for example, as coatings. Thus tablets or pills
may be coated With sugar, shellac, or other enteric coating
agents. A syrup may contain, in addition to the active
compounds, sucrose as a sWeetening agent and certain

preservatives, dyes and coloring and ?avors. Materials used
in preparing these various compositions should be pharma
ceutically or veterinarally pure and non-toxic in the amount
used.

MOMCl, DIPEA

—>

cnzcl2

US 7,064,202 B1
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EXAMPLE 2

-continued

Synthesis of camptothecin-20-O-ester of
N-methylglycine, mono (tri?uoroacetate)

O
O
NHBOC
HO

O

U

n

n I 1, 2, 3

EDCl, DMAP, cnzcl2

a. EDCl, DMAP, CHZCIZ,
BOC

\IiI/Y
CH3

OH

o

O

20

O

O

BOC

/ W1“
25

0

CH3
0

30

o

0

CH3

YN/ CF3COOH
H

o
35

Brie?y, SN-38 (1 equiv) Was dissolved in anhydrous

A solution of camptothecin (100 mg, 0.29 mmol), N-(tert
butoxycarbonyl)metylyglycine (136 mg, 0.72 mmol) and
DMAP(14 mg, 0.12 mmol) in 10 ml anhyd. dichlo

dichloromethane, and diisopropyl ethyl amine (DIPEA) (5
equiv) Was added under nitrogen atmosphere. The reaction
mixture Was stirred for 10 min at room temperature followed

by the addition of methoxylmethylchloride (MOMCl) (5

40

equiv). The resulting solution Was left stirring overnight.

alloWed to come to room temperature and stirred overnight.

The reaction Was terminated. Then the reaction mixture Was

diluted by dichloromethane and Washed several times With
Water, dried (MgSO4), ?ltered, and concentrated. Puri?ca
tion by chromatography on silica gel gave 10-MOM pro

45

tected compound.

1-Ethyl-3 -(3 -dimethylaminopropyl)carbodiimide (EDCI,
3 equiv) Was sloWly added to a solution of 10-MOM

protected compound (1 equiv), tert-butoxycarbonylamino

50

acid (3equiv) and 4-(dimethylamino)pyridine (DMAP, 0.6
equiv) and anhydrous dichloromethane, Which had been
precooled to 00 C. The resulting solution Was alloWed to
Warm to room temperature and stirred overnight. The

organic fraction Was Washed With HCl (0.1 N) and Water and

55

then extracted several times With CH2Cl2. Organic layers

60

by stirring MOM and N-BOC protected prodrug in dichlo
romethane and tri?uoracetic acid for 30 minutes at room

Was found to be greater than 98% pure.

(CH2Cl24CH3COCH3, 9:1) gave solid (126 mg, 85%).
lHNMR (400 MHZ, CDCl3): 1.00 (t, J:7.2, 3H), 1.44 (d,
1:92, 9H), 20542.25 (m, 2H), 2.95 (s, 3H), 40341.32 (AB
system, 2H), 5.30 (s, 2H), $3245.43 (A ofAB system, 1H),
56845.73 (B of AB system, 1H), 7.19, 7.37 (ss, 1H),
7.634769 (m, 1H), 7.8(%7.85 (m, 1H), 7.94 (t, 1:84, 1H),
8.164825 (dd, 1:292, 1:84, 1H), 8.38 (d, 1:132, 1H).
Camptothecin-20-O-ester of N-tert-butoxycarbonylmeth
ylglycine (100 mg, 0.19 mmol) Were dissolved in dichlo

under high vacuum. RecrystaliZation by methanol and ethyl
ether obtained solid 96 mg, yield 94%. lHNMR (400 MHZ,

of MOM and N-BOC groups Was achieved simultaneously

temperature, folloWed by concentration under high vacuum
and recrystaliZation in methanol and ethyl ether. Purity of
?nal products Was determined by HPLC and prodrug purity

The resulting solution Was Washed With HCl (5 ml, 0.1 N)
and Water, then extracted With dichloromethane. The organic
layer Was dried With MgSO4, then ?ltered and concentrated.
Puri?cation by column chromatography on silica gel

romethane and tri?uoracetic acid, then stirred 30 min. at
room temperature. The yelloW solution Was concentrated

Were combined and dried With MgSO4, folloWed by ?ltra
tion and concentration. Puri?cation of this residue by ?ash

chromatography on silica gel gave chloromethyl methyl
ether (MOM) and N-BOC protected prodrug. Deprotection

romethane Was cooled to 00 C., folloWed by the addition of
EDCI(110 mg, 0.57 mmol). The reaction mixture Was

65

DMSO): 0.96 (t, J:7.23H), 2.1(%2.22 (m, 2H), 2.61 (s, 3H),
4.284450 (AB system, 2H), 52745.38 (AB system, 2H),
5.56 (s, 2H), 7.27 (s, 1H), 7.74 (t, 1:76, 1H), 7.88 (t, 1:76,
1H), 8.144817 (d, 1:96, 2H), 8.73 (s, 1H), 9.15 (brs, 1H);
l3CNMR (400 MHZ, DMSO): 7.56, 30.13, 32.53, 47.88,
50.31, 66.39, 77.71, 95.30, 118.85, 127.84, 128.04, 128.67,
128.78, 129.83, 130.60, 131.75, 144.58, 146.17, 147.90,
152.33, 156.50, 166.10, 166.82

US 7,064,202 B1
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EXAMPLE 3

glycinate esters Were studied). Prodrug decomposition Was
observed in phosphate buffered saline (PBS) at pH 7.4, as

Conversion of camptothecin and SN-38 20(S) u)
aminoalkanoanic esters to lactam, ortho lactone and

Well as in human plasma and blood.
The presence of the amine functionality Was found to be

acetic acid Prodrugs

essential for the prodrug decomposition. Whereas camptoth
ecin-20(S)-glycinate l [1 uM, PBS (pH 7.4), 370 C.] under
Went extensive decomposition (~90%) Within 3 hours, its

The procedure involves placing in solution a 20-OR
uu-aminoalkanoanic ester of camptothecin or SN-38, in
Which R:CO[CH2]nNH2 and n:lI3. The basic amino group
of the prodrug serves three roles. First, at pH ranges of 3 to

corresponding aliphatic ester analog camptothecin-20(S)
acetate (differing solely by the replacement of the amino
group With a proton) demonstrated excellent stability in the

5, it enhances aqueous solubility. Second, it enhances

above ?uids for days With negligible evidence of hydrolysis.
Amine-containing esters of camptothecin With longer alkyl
functionalities
(RICOCHZCHZNHZ,

responsiveness to a transmembrane ammonium sulfate gra

dient across the liposomal bilayer, thereby facilitating active
loading of the agent into the liposomal aqueous core. Third,

R:COCH2CH2CH2NH2) also reacted under similar condi
tions, albeit at a sloWer rate (half-lifes of 26.4 hr and 36.7 hr,

at a physiological pH of 7 or above (the pH to be encoun

tered folloWing drug release at the tumor site), the nucleo
philicity of the amine manifests itself and cycliZation to the
C-21 carbonyl carbon occurs. This cycliZation triggers a

respectively) than their glycinate counterparts.
20

To better understand the mechanism of pro drug decom

rapid and convenient non-enZymatic decomposition process

position, RP-HPLC coupled With electrospray ioniZation

that releases active camptothecin.

tandem mass spectrometry (ESl-MS/MS) and 13 C, 15N, and
2D NMR experiments Were used to study the decomposition

In contrast to l0-OR-CPT-20-OH compounds such as

CPT-ll, Which are knoWn to exhibit hydrolysis-resistant

carbamate bonds that require enZymatic cleavage, reversed

25

phase high performance liquid chromatographic (RP-HPLC)

carboxylate form of camptothecin 6, and tWo novel decom
position products 3 and 4 generated folloWing the formation
of an unusual six membered morpholine 2,5-dione ring 2 (or
lactam intermediate).

studies of the stabilities of several l0-OH-CPT-20-OR and

CPT-20-OR

glycinate

ester

prodrugs

reaction of camptothecin-20(S)-glycinate. Camptothecin-20
(S)-glycinate l decomposed to produce several products: the
closed-ring lactone form of camptothecin 5, the ring-opened

(Where

RICOCHZNH2) revealed extensive chemical (i.e. non-en
Zymatic) decomposition in every case (CPT and SN-38

Glycinate Ester of
CPT (R1 I H, R3 I H);
SN—38 (R1 I CH2CH3, R3 I OH)

65

The lactam intermediate arose by intramolecular nucleo
philic attack of the amino group on the lactone E-ring

carbonyl carbon of camptothecin and is in fast equilibrium
With structures 3 (Which We refer to as the ortho lactone) and

US 7,064,202 B1
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4. Ortho lactone 3 arose by a second intramolecular reaction
Within the lactam intermediate and 3 exhibited the same

-continued

mass as camptothecin-20(S)-glycinate ester but With a strik

ingly different fragmentation pattern. 4 arose by a competi
tive intermolecular reaction to the lactam intermediate and
reacted to release both 5 and 6. HPLC-ESI-MS full scan

shoWed the mass values for the protonated molecular (MH+)

ions of camptothecin glycinate ester degradation products
Were: 1 (406), 3 (406), 4 (424), 5 (349), 6 (389).
MS/MS shoWed that CPT glycinate ester 1 and CPT ortho
lactone 3 Were isomers With different fragmentation pattern.

CPT glycinate fragmentation pattern [m/Z(%)] Was: 406
(25%), 331 (100%), 303 (30%); CPT ortho lactone frag
mentation pattern Was: 406 (100%), 388 (40%), 303 (20%).
Likewise, N-substituted glycinate ester analogs of other

Atom

DMSO ppm

#

6C

6B

Observed Coupling

camptothecins (1 11M, in PBS, pH 7.4), including SN-38,

12

129.0

8.17(1H)

3JCH 11-10

underWent extensive decomposition (~90%) Within 3 hours.

13

147.9

f

3JCH 117,119, 11 11

HPLC data for each analog studied Was consistent With the

14

100.4

7.26(1H)

JCH H-17b

15

150.6

f

3JCH H—19b,H-17a

16

128.2

f

2JCH H-l7él, H-17b; 3JCH H-14

17

57.4

4.83(1H, a),

i

generation of the novel decomposition products, along With

20

the lactone and carboxylate forms of the parent drug. ESI
MS/ MS analysis indicated that the proposed ortho lactone 3

5.03(111, b)

generated for N-methyl CPT glycinate ester displayed the
same mass as the ester but With a different fragmentation

pattern. HPLC-ESI-MS full scan shoWed the mass values for

7.9
33.1

0.92(311)
2.05(111, a),

2JCH H-l9él, H-19b
2JCH 11-18

20
21

82.0
166.6

i
f

2JCH H-l9él, H-19b; 3JCH 11-14, 11-1
3JCH H-l9él, 11-26; 6JCH H-17b

23

54.8

3.41(111, a),

3JCH H-26, OH

2.35(111, b)
25

the protonated molecular (MH+) ions of N-methyl camp
tothecin glycinate ester degradation products Were: 1 (420),
3 (420), 4 (438), 5 (349), 6 (389). MS/MS shoWed that
N-methyl CPT glycinate ester 1 and CPT N-methyl ortho
lactone 3 Were isomers With different fragmentation pattern.

18
19

3.71(111, b)
24

107.1

f

2JCH H-23é1, H-23b, OH; 3JCH H-17

26

34.1

2.85(3H)

3JCH H-233.

4

8.06(1H)

4

H-17b; ‘*JCH H-26
30

N-methyl CPT glycinate fragmentation pattern [m/Z(%)]

OH

Was: 420 (86%), 331 (100%), 303 (30%); CPT N-methyl
ortho lactone fragmentation pattern Was: 420 (100%), 402
(50%), 303 (37%). As in the case for the camptothecin
glycinate ester, the novel degradation products Were gener
ated from the proposed lactam intermediate. Further evi
dence for proposed degradation products 3 and 4 includes:

EXAMPLE 4
35

Procedure for the Isolation of the ortho lactone

from CPT-N-methyl glycinate

(1) Glycine carbonyl 13 C isotopic labeling NMR experiment
in PBS shoWing that this carbon exists as a tetrahedral

carbon as in 3. (2) Glycine l5N isotopic labeling NMR
experiments shoWing that 3 and 4 have amide bonds. (3) 2D
NMR spectrum of isolated N-methyl camptothecin ortho

40

Camptothecin N-methyl glycinate tri?uoroacetic acid salt
Was dissolved in DMF, 1.2 eq. triethylamine Was then added

and reaction stirred overnight at room temperature. Organic
solvent Was removed and a yelloW precipitate Was rinsed
With Water, ?ltered, and dried under vacuum. Yield: 98%.

lactone 3
45

EXAMPLE 5

Procedure for the Isolation of the ortho lactone

from SN-38 methyl glycinate ester
50

SN-38 N-methyl glycinate tri?uoroacetic acid salt Was
dissolved in unhydrous DMF, 1.5 eq. triethylamine Was then
added and reaction stirred overnight at room temperature.
55

Organic solvent Was removed and residue Was rinsed With
Water to remove salt, SN-38 N-methyl ortho lactone Was

extracted With ethyl acetate.
#

6C

6B

Observed Coupling

2
3

152.8
142.7

f
f

3JCH 11-5, 11-7, 11-14
2JCH 11-14; 5JCH H-17b

5

50.0

5.26(2H)

3JCH H-7

6

129.8

f

2JCH H-5

7

131.5

8.66(1H)

3JCH 115,119

8

127.5

f

9
10
11

128.5
127.8
130.3

8.08(1H)
7.69(1H)
7.86(1H)

EXAMPLE 6
60

Procedure for the Isolation of the ortho lactone

from 9-NC-methyl glycinate ester

i

JCH 11-7
JCH 11-12
JCH 11-9

9-Nitro Camptothecin N-methyl glycinate hydrocholoride
65

Was dissolved in DMF, 1.5 eq. triethylamine Was then added

and reaction stirred overnight at room temperature. Organic
solvent Was removed and residue Was dried under vacuum.

US 7,064,202 B1
17

18
What is claimed:
1. A compound With the formula:

EXAMPLE 7

Procedure for the Isolation of the Ortho Lactone

from 10,11-MDCPT-20-glycinate ester

10,11-methylenedioxy Camptothecin N-methyl glycinate
hydrocholoride Was dissolved in anhydrous dichlo
romethane, 1.5 eq. triethylamine Was added and reaction
stirred overnight at room temperature. Organic solvent Was
removed and residue Was rinsed With Water and dried under
vacuum.

EXAMPLE 8

LC/MS Condition for Elucidation of Degradation
Products of Camptothecin-20(S)-Glycinate in

Aqueous Solution
where R1 may be: a) hydrogen, a halogen atom, a
branched or linear alkyl group, a branched or linear
alkenyl group, a branched or linear alkynyl group, a

The LC/MS system consisted of an HP 1100 HPLC
equipped With a 50><1.0 mm id. (3 micron) Luna C18

cycloalkyl group, a cycloalkenyl group, an alkoxy

microbore column (Phenomex, Torrence, Calif). lsocratic
separations Were preformed at 35 uL/min using 80% aceto
nitrile and 20% 10 mM ammonium for'mate pH 5.5. Salts in
the samples Were diverted from the mass spectrometer
during the ?rst tWo minutes of each experiment. Electro
spray mass spectra Were acquired on a Finnigan LCQ

Classic (San Jose, Calif.) quadrupole ion trap mass spec
trometer in the positive ion mode. Standard electrospray

25

group, an alkylamino group, a dialkylamino group, an
alkylthiol group, a thiol group, a phenyl group, an
amino group, a nitro group, a cyano group; b) a

(CH2)YNR8R9 group, WhereinY is an integer from 1410
and R8 and R9 are, independently, hydrogen, an alkyl
30

group, an alkenyl group, an alkynyl group, an amine, an

alkyl amine, a dialkyl amine, a hydroxy group, an
alkoxy group, an acyl group, a carbamate;
R2 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl

conditions Were used (spray voltage 4.5 kV, shealth gas ?oW
rate 60 arb. units, and capillary temp. 2250 C.). Full scan
mass spectra Were obtained over a range of 100 to 1000 m/Z. 35

Typical tandem mass spectra parameters Were 3 m/Z isola

group, a linear or branched alkynyl group, an amino
group, an alkylamino group, a dialkylamino group, a

tion Width, 35% normaliZed collision energy, qZ:0.25 and

nitro group, a 3410 membered heterocyclic ring, a

CID time of 30 ms.

C3_1O cycloalkyl group, a C3_l0 cycloalkenyl group, a
C8_1O cycloalkynyl group, a thiol group, a cyano group;
EXAMPLE 9

40

b) a (CH2)YNR8 R9 group, WhereinY is an integer from
1410 and R8 and R9 are, independently, hydrogen, an
alkyl group, an alkenyl group, an alkynyl group, an

Remote “active” loading of prodrug into premade small

amine, an alkyl amine, a dialkyl amine, a hydroxy

unilamellar vesicles, With diameters of 100 nm, Was carried

group, an alkoxy group, an acyl group, a carbamate;
R3 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl

out by using transmembrane ammonium sulfate gradients.

45

Prodrug Was added to a liposomal suspension Where initially

[(NH4)2SO4]CORE' [(NH4)2SO4]EXTERNAL; loading of the

group, a linear or branched alkynyl group, an amino
group, an alkylamino group, a dialkylamino group, a

prodrug occurred as a result of base exchange (initiated by

NH3 gas molecules departing the liposome). Whereas
underivatiZed camptothecin and DB-67 localiZe predomi
nantly in the bilayer compartment of the liposome, their
20-OR prodrugs, Where R) CO[CH2]nNH 2 and n) 143,
loaded With high ef?ciency (60 to 90%) into the core of

liposomes at clinically relevant drug-to-lipid ratios (betWeen

50

55

1:4 to 1:20). More importantly, these core-loaded liposomal
formulations of camptothecin 4-aminobutanoate ester and
DB-67 4-aminobutanoate ester exhibited markedly
improved stabilities in Whole blood relative to their free
forms. Whereas the decomposition of free prodrug in both
cases Was extensive, liposomal entrapment prevented the

a dialkyl amine, a hydroxy group, an alkoxy group, an

acyl group, a carbamate;
R4 may be hydrogen, a halogen atom, a hydroxy group, an
amino group, a methoxy group, an alkyl group, an
alkynyl group or an alkenyl group;
60

R5 may be hydrogen or ?uorine;
R6 may be an alkyl group, an alkenyl group, an alkynyl

degradation process from occurring, providing indirect evi
dence that the prodrug was effectively retained Within the
liposome for periods up to 40 h. These time periods are
knoWn to be suf?cient for successful tumor-targeting to be
achieved.

nitro group, a C3_1O cycloalkyl group, a C3_1O cycloalk
enyl group, a C8_1O cycloalkynyl group, a thiol group,
a cyano group, a hydroxyl group; b) a (CH2)YNR8R9
group, WhereinY is an integer from 1410 and R8 and R9
are, independently, hydrogen, an alkyl group, an alk
enyl group, an alkynyl group, an amine, an alkyl amine,

group, or a benZyl group;
65

R7 may be hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, a benZyl group, an alkoxy group, an
aryloxy group, or an acyloxy group; and pharmaceuti

cally acceptable salts thereof.

US 7,064,202 B1
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2. A compound With the formula:

C3_1O cycloalkyl group, a C3_l0 cycloalkenyl group, a
C87l0 cycloalkynyl group, a thiol group, a cyano group;
b) a (CH2)YNR8R9 group, WhereinY is an integer from
lil0 and R8 and R9 are, independently, hydrogen, an
alkyl group, an alkenyl group, an alkynyl group, an

amine, an alkyl amine, a dialkyl amine, a hydroxy
group, an alkoxy group, an acyl group, a carbamate;
R3 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl
group, a linear or branched alkynyl group, an amino
group, an alkylamino group, a dialkylamino group, a

on

nitro group, a 3*l0 membered heterocyclic ring, a

NR7| w
0

C3_1O cycloalkyl group, a C3_l0 cycloalkenyl group, a
C8_1O cycloalkynyl group, a thiol group, a cyano group,

a hydroxyl group; b) a (CH2)YNR8R9 group, WhereinY
is an integer from lil0 and R8 and R9 are, indepen
dently, hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, an amine, an alkyl amine, a dialkyl
amine, a hydroxy group, an alkoxy group, an acyl

where R1 may be: a) hydrogen, a halogen atom, a
branched or linear alkyl group, a branched or linear
alkenyl group, a branched or linear alkynyl group, a

cycloalkyl group, a cycloalkenyl group, an alkoxy

20

(CH2)YNR8R9 group, WhereinY is an integer from lil0
and R8 and R9 are, independently, hydrogen, an alkyl

amino group, a methoxy group, an alkyl group, an
alkynyl group or an alkenyl group;

R5 may be hydrogen or ?uorine;
25

group, an alkenyl group, an alkynyl group, an amine, an

group, a linear or branched alkynyl group, an amino
group, an alkylamino group, a dialkylamino group, a

nitro group, a 3*l0 membered heterocyclic ring, a

R6 may be an alkyl group, an alkenyl group, an alkynyl
group, a benZyl group, an alkoxy group, an aryloxy
group, or an acyloxy group;

alkyl amine, a dialkyl amine, a hydroxy group, an
alkoxy group, an acyl group, a carbamate;
R2 may be: a) hydrogen, a halogen atom, a linear or
branched alkyl group, a linear or branched alkenyl

group, a carbamate;

R4 may be hydrogen, a halogen atom, a hydroxy group, an

group, an alkylamino group, a dialkylamino group, an
alkylthiol group, a thiol group, a phenyl group, an
amino group, a nitro group, a cyano group; b) a

R7 may be hydrogen, an alkyl group, an alkenyl group, a
benZyl group, an alkoxy group, an aryloxy group, or an
30

acyloxy group; and
R8 may be hydrogen, an alkyl group, or an alkenyl group;
and

pharmaceutically acceptable salts thereof.
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